BNP Paribas Arbitrage SNC Purchases 133,290 Shares of Hologic, Inc. (NASDAQ:HOLX)

BNP Paribas Arbitrage SNC raised its position in Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 88.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 284,129 shares of the medical equipment provider’s stock after acquiring an additional 133,290 shares during the quarter. BNP Paribas Arbitrage SNC owned approximately 0.11% of Hologic worth $18,332,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Salem Investment Counselors Inc. increased its stake in Hologic by 163.9% in the second quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 341 shares during the last quarter. Lansing Street Advisors acquired a new position in shares of Hologic during the third quarter worth $44,000. Neo Ivy Capital Management acquired a new position in shares of Hologic during the second quarter worth $56,000. Quadrant Capital Group LLC lifted its holdings in Hologic by 23.2% in the second quarter. Quadrant Capital Group LLC now owns 929 shares of the medical equipment provider’s stock valued at $64,000 after buying an additional 175 shares during the period. Finally, Private Trust Co. NA acquired a new position in Hologic in the second quarter valued at $64,000. Institutional investors own 95.17% of the company’s stock.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $79.36 on Wednesday. The company’s fifty day moving average price is $80.95 and its 200-day moving average price is $73.85. The firm has a market capitalization of $19.57 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 1.37 and a beta of 1.01. Hologic, Inc. has a one year low of $59.78 and a one year high of $86.65. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.21 and a quick ratio of 3.50.

Hologic (NASDAQ:HOLX – Get Rating) last announced its quarterly earnings results on Wednesday, February 1st. The medical equipment provider reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.17. Hologic had a net margin of 22.17% and a return on equity of 25.12%. The business had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the prior year, the company posted $2.17 EPS. The firm’s revenue for the quarter was down 27.0% compared to the same quarter last year. On average, equities research analysts anticipate that Hologic, Inc. will post 3.74 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In related news, insider Benjamin Jordan Cohn sold 9,128 shares of the firm’s stock in a transaction that occurred on Tuesday, February 7th. The shares were sold at an average price of $85.28, for a total value of $778,435.84. Following the transaction, the insider now owns 14,298 shares of the company’s stock, valued at $1,219,333.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.66% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. SVB Leerink boosted their target price on shares of Hologic from $90.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 2nd. Citigroup lifted their price target on shares of Hologic from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Thursday, February 2nd. Morgan Stanley lifted their price target on shares of Hologic from $74.00 to $81.00 and gave the company an “equal weight” rating in a research note on Friday, February 3rd. Royal Bank of Canada began coverage on shares of Hologic in a research report on Tuesday, December 6th. They set a “sector perform” rating and a $75.00 target price for the company. Finally, Mizuho boosted their price target on shares of Hologic from $77.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, January 24th. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $84.08.

Hologic Company Profile

(Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.